Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment

Peter James Dyck, Peter C. O'Brien, Karen F. Oviatt, Robert P. Dinapoli, Jasper R. Daube, John D. Bartleson, Bahram Mokri, Thomas Swift, Phillip A. Low, Anthony J. Windebank

Research output: Contribution to journalArticlepeer-review

414 Scopus citations


Of 40 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), 28 completed a controlled three‐month trial of prednisone. Prednisone was shown to cause a small but significant improvement over no treatment in scored neurological disability, some measures of computer‐assisted sensory detection threshold, graded muscle strength, and some attributes of nerve conduction. No subset of patients was more likely than another to be responsive to prednisone; those with a progressive course were as likely to be responsive as recurrent cases. This finding provides further justification for classifying progressive with recurrent cases as CIDP and demonstrates that prednisone treatment should not be withheld from patients with progressive disease.

Original languageEnglish (US)
Pages (from-to)136-141
Number of pages6
JournalAnnals of neurology
Issue number2
StatePublished - Feb 1982

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment'. Together they form a unique fingerprint.

Cite this